These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33093601)

  • 1. Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.
    Varela MC; Roch M; Taglialegna A; Long SW; Saavedra MO; Rose WE; Davis JJ; Hoffman LR; Hernandez RE; Rosato RR; Rosato AE
    Commun Biol; 2020 Oct; 3(1):599. PubMed ID: 33093601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
    Andrey DO; François P; Manzano C; Bonetti EJ; Harbarth S; Schrenzel J; Kelley WL; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):343-350. PubMed ID: 27744604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.
    Long SW; Olsen RJ; Mehta SC; Palzkill T; Cernoch PL; Perez KK; Musick WL; Rosato AE; Musser JM
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6668-74. PubMed ID: 25155594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus.
    Lee H; Yoon EJ; Kim D; Kim JW; Lee KJ; Kim HS; Kim YR; Shin JH; Shin JH; Shin KS; Kim YA; Uh Y; Jeong SH
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
    Alm RA; McLaughlin RE; Kos VN; Sader HS; Iaconis JP; Lahiri SD
    J Antimicrob Chemother; 2014 Aug; 69(8):2065-75. PubMed ID: 24777906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
    Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K
    J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Alm RA; Lahiri SD; Reiszner E; Hoban DJ; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):343-7. PubMed ID: 26503659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
    Fernandez R; Paz LI; Rosato RR; Rosato AE
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5736-46. PubMed ID: 25022592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.
    Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
    Lahiri SD; McLaughlin RE; Whiteaker JD; Ambler JE; Alm RA
    J Antimicrob Chemother; 2015 Sep; 70(9):2488-98. PubMed ID: 26045529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic analysis of Italian MRSA strains exhibiting low-level ceftaroline and ceftobiprole resistance.
    Bongiorno D; Mongelli G; Stefani S; Campanile F
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114852. PubMed ID: 31288948
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.
    Schaumburg F; Peters G; Alabi A; Becker K; Idelevich EA
    J Antimicrob Chemother; 2016 Jan; 71(1):41-4. PubMed ID: 26443816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure.
    Cannavino CR; Mendes RE; Sader HS; Farrell DJ; Critchley IA; Biek D; Le J; Skochko SM; Jones RN; Bradley JS
    Pediatr Infect Dis J; 2016 Jul; 35(7):813-5. PubMed ID: 27093165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
    Chan LC; Basuino L; Diep B; Hamilton S; Chatterjee SS; Chambers HF
    Antimicrob Agents Chemother; 2015 May; 59(5):2960-3. PubMed ID: 25753637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
    Nigo M; Diaz L; Carvajal LP; Tran TT; Rios R; Panesso D; Garavito JD; Miller WR; Wanger A; Weinstock G; Munita JM; Arias CA; Chambers HF
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28232309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
    Yoneda A; Thänert R; Burnham CD; Dantas G
    Int J Antimicrob Agents; 2020 Feb; 55(2):105864. PubMed ID: 31870598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis.
    Champion EA; Miller MB; Popowitch EB; Hobbs MM; Saiman L; Muhlebach MS;
    Pediatr Pulmonol; 2014 Mar; 49(3):230-7. PubMed ID: 23765686
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Gostev V; Sopova J; Kalinogorskaya O; Tsvetkova I; Lobzin Y; Klotchenko S; Sidorenko S
    Microb Drug Resist; 2019 Dec; 25(10):1401-1409. PubMed ID: 31329022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.